Men's health study: Epidemiology of erectile dysfunction and cardiovascular disease

Circulation Journal

Volumn 67, Issue 8, 2003, Pages 656-659

  Sasayama, Shigetake ^a   Ishii, Nobuhisa ^b   Ishikura, Fuminobu ^c   Kamijima, Gombei ^b   Ogawa, Satoshi ^d   Kanmatsuse, Katsuo ^e   Kimoto, Yasusuke ^f   Sakuma, Ichiro ^g   Nonogi, Hiroshi ^h   Matsumori, Akira ⁱ   Yamamoto, Yasuhiro ^j  

^a HAMAMATSU ROSAI HOSPITAL   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SPINAL INJURIES CENTER   (Japan)

^g HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

ⁱ KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j NIPPON MEDICAL SCHOOL   (Japan)

more..

Author keywords

Cardiovascular disease; Comorbidity; Endothelium; Erectile dysfunction; Risk factors

Indexed keywords

SILDENAFIL;

ADULT; AGED; AGING; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG MECHANISM; ERECTILE DYSFUNCTION; GENERAL PRACTITIONER; HEALTH SURVEY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL EXAMINATION; OUTPATIENT DEPARTMENT; RISK; RISK FACTOR; SOCIETY; TABLET FORMULATION; VASCULAR ENDOTHELIUM;

EID: 10744232172     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.67.656     Document Type: Article

References (19)

1. Shirai M. Epidemiology of ED and risk actors. Rinsyo to Kenkyu 1999; 765: 841-843.
2. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83(5A): 3C-12C.
3. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.
4. Sasayama M, Ishii N, Ishikura F, Ueshima G, Ogawa S, Uematsu S, et al. The first report: The Cardiovascular Issue Examining Committee of Viagra. Nihon Junkanki Gakkai Kaikoku 1999; 7: 1-11.
5. Sasayama M, Ishii N, Ishikura F, Ueshima G, Ogawa S, Uematsu S, et al. The second report: The Cardiovascular Issue Examining Committee of Viagra. Nihon Junkanki Gakkai Kaikoku 1999; 10: 1-6.
6. The Terminology Committee of The Japanese Society for Impotence Research. [Japanese translation of] the International Index of Erectile Function and of the 5-Item Version of the International Index of Erectile Function (IIEF-5). Impotence 1998; 131: 35-38.
7. Mizuno K, Muraishi Y, Fuse H. Comparative study of subjective erectile function and objective erectile function evaluated by IIEF-5 and NPT test. J Jpn Assoc Imp Res 2000; 152: 236-237.
8. Furukawa T, Anraku K, Hiroe T, Takahashi K, Kitamura T, Hirai T, et al. Screening for depression among first-visit psychiatric patients: Comparison of different scoring methods for the Center for Epidemiologic Studies Depression Scale using receiver operating characteristic analyses. Psychiatry Clin Neurosci 1997; 51: 71-78.
9. st edn. Tokyo: Igaku Tosho Syuppan Kabusikikaisya; 1997: 6-7.
10. st edn. Tokyo: Medical View, 2000; 10-15.
11. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann. Epidemiology of erectile dysfunction: Results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12: 305-311.
12. Rosen RC, Cappetteri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319-326.
13. Marumo K, Nakashima J, Murai M. Age-related prevalence of erectile dysfunction in Japan: Assessment by the International Index of Erectile Function. Int J Urol 2001; 82: 53-59.
14. Marui E. Epidemiology of ED (erectile dysfunction) and risk factors. Igaku no Ayumi 2002; 201: 397-400.
15. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study. J Urol 1994; 151: 54-61.
16. Yoshimoto K. About sildenafil citrate (Viagra™). Nihon Iyakuhin Joho 1998; 15: 1-4.
17. Dakeshita H, Yamashita N, Maruoka Y, Imamura M, Ueki T, Shigeta F. The survey of safety and efficacy of Viagra-Tablet in Japan. Rinsyo to Kenkyu 2002; 799: 1655-1661.
18. Herrmann HC, Chang G, Klucherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622-1626.
19. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845-851.